Cardiac functions by myocardial performance index and QT dispersion in survivors of childhood lymphoblastic leukaemia

Minerva Pediatrica

Volumn 59, Issue 2, 2007, Pages 107-113

  Gulen, H ^a,b   Kazanci, E ^a   Mese, T ^a   Uzunkaya, D ^a   Erbay, A ^a   Tavli, V ^a   Vergin, C ^a  

^a DR BEHÇET UZ CHILDREN'S HOSPITAL   (Turkey)

^b NONE   (Turkey)

Author keywords

Child; Heart, physiology; Lymphoblastic leukemias

Indexed keywords

ANTHRACYCLINE DERIVATIVE; DAUNORUBICIN; DOXORUBICIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CHILD; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HEART FUNCTION; HEART PERFORMANCE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; NEWBORN; QT DISPERSION;

ADOLESCENT; ANTIBIOTICS, ANTINEOPLASTIC; CHILD; CHILD, PRESCHOOL; DAUNORUBICIN; DOXORUBICIN; ECHOCARDIOGRAPHY, DOPPLER; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; LEUKEMIA, LYMPHOCYTIC; MALE; SURVIVORS; TIME FACTORS;

EID: 34250876298     PISSN: 00264946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Gupta M, Thaler HT, Steinherz L. Presence of prolonged dispersion of QT intervals in late survivors of childhood anthracycline therapy. Pediatr Hematol Oncol 2002;19:533-42.
2. Elbl L, Hrstkova H, Chaloupka V. The late consequences of anthracycline treatment on left ventricular function after treatment for childhood cancer. Eur J Pediatr 2003;162:690-6.
3. Billingham ME, Masek MA. The pathology of anthracycline cardiotoxicity in children, adolescents and adults. In: Bricker JT, Gren DM, D'Angio G, editors. Cardiac toxicity after treatment for childhood cancer. New York:Wiley Liss;1993. p. 17-24.
4. Giantris A, Abdurrahman L, Hinkle A, Asselin B, Lipshultz SE. Anthracycline-induced cardiotoxicity in children and young adults. Crit Rev Oncol Hematol 1998;27:53-68.
5. Von Hoff DD, Rozencweig M, Layard M, Slavik M, Muggia FM. Daunomycin-induced cardiotoxicity in children and adults. Am J Med 1977;62:200-8.
6. Von Hoff DD, Layard MW, Basa P, Davis HL, Von Hoff AL, Rozencweig M et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Int Med 1979;91:710-7.
7. Steinherz LJ, Graham T, Hurwitz R, Sondheimer HM, Schwartz RG, Shaffer EM et al. Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the cardiology committee of the children's cancer study group. Pediatrics 1992;89:942-9.
8. Shan K, Lincoff M, Young JB. Anthracycline induced cardiotoxicity. Ann Intern Med 1996;125:47-58.
9. Tei C. New non-invasive index for combined systolic and diastolic ventricular function. J Cardiol 1995;26:135-6.
10. Tei C, Ling LH, Hodge DO, Bailey KR, Oh JK, Rodeheffer RJ et al. New index of combined systolic and diastolic myocardial performance: a simple and reproducible measure of cardiac function. A study in normal and dilated cardiomyopathy. J Cardiol 1995;26:357-66.
11. Vloka ME, Steinberg JS. QT dispersion: current and future clinical role. J Invas Cardiol 1996;8:363-9.
12. Buja G, Miorelli M, Turrini P, Melacini P, Nava A. Comparison of QT dispersion in hypertrophic cardiomyopathy between patients with and without ventricular arrhythmias and sudden death. Am J Cardiol 1993;72:973-6.
13. Perkioaki JS, Koistinen MJ, Yli-Mayry S, Huikuri HV. Dispersion of QT interval in patients with and without susceptibility to ventricular tachyarrhythmias after previous myocardial infarction. J Am Coll Cardiol 1995;26:174-9.
14. Barr CS, Naas A, Freeman M, Lang CC, Struthers AD. QT dispersion and sudden expected death in chronic heart failure. Lancet 1994;343:327-9.
15. Zareba W, Moss AJ, le Cessie S. Dispersion of ventricular repolarization and arrhythmic cardiac death in coronary artery disease. Am J Cardiol 1994;74:550-3.
16. Ishii M, Eto G, Tei C, Tsutsumi T. Quantitation of the global right ventricular function in children with normal heart and congenital heart disease: a right ventricular myocardial performance index. Pediatr Cardiol 2000;21:416-21.
17. Bazett HC. An analysis of time relationships of the heart. Heart 1920;7:353-70.
18. Ritchie JL, Singer JW, Thorning D, Sorensen SG, Hamilton GW. Anthracycline cardiotoxicity: clinical and pathologic outcomes assessed by radionuclide ejection fraction. Cancer 1980;46:1109-16.
19. Steinherz L, Steinherz P. Delayed cardiac toxicity from anthracycline therapy. Pediatrician 1991;18:49-52.
20. Steinherz LJ, Steinherz PG, Tan CTC, Heller G, Murphy L. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991;266:1672-7.
21. Grenier MA, Lipshultz SE. Epidemiology of anthracycline cardiotoxicity in children and adults. Semin Oncol 1998;25:72-85.
22. Eidem BW, Sapp BG, Suarez CR, Cetta F. Usefulness of the myocardial performance index for early detection of anthracycline-induced cardiotoxicity in children. Am J Cardiol 2001;87:1120-2.
23. Kremer LCM, van der Pal HJH, Offringa M, van Dalen EC, Voute PA. Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Ann Oncol 2002;13:819-29.
24. Nysom K, Colan SD, Lipshultz SE. Late cardiotoxicity following anthracycline therapy for childhood cancer. Progress Pediatr Cardiol 1998;8:121-38.
25. Bender KS, Shematek JP, Leventhal BG, Kan JS. QT interval prolongation associated with anthracycline cardiotoxicity. J Pediatr 1984;105:442-4.
26. Schouten EG, Dekker JM, Meppelink P, Kok FJ, Vandenbrouke JP, Pool J. QT interval prolongation predicts cardiovascular mortality in an apparendy healthy population. Circulation 1991;84:1516-23.
27. Algra A, Tijessen JGP, Roelandt JRTC, Pool J, Lubsen J. QTc prolongation measured by standart 12 lead electrocardiogram is an independent risk factor for sudden death due to cardiac arrest. Circulation 1991;83:1888-94.
28. Nousiainen T, Vanninen E, Rantala A, Jantunen E, Hartikainen J. QT dispersion and late potentials during doxorubicin therapy for non-Hodgkin's lymphoma. J Intern Med 1999;245:359-64.
29. Owecki M, Michalak A, Nikisch E, Sowinski J. Prolonged ventricular repolarization measured by QTc interval in hyperthyroidism. Pol Merkuriusz Lek 2005;19:24-7.
30. Weinbrenner C, Gerbert B, Strasser RH. Thyroid hormone and the cardiovascular system. Dtsch Med Wochenschr 2005;130:2215-9.
31. Benoit SR, Mendelsohn AB, Nourjah P, Staffa JA, Graham DJ. Risk factors for prolonged QTc among US adults: Third National Health and Nutrition Examination Survey. Eur J Cardiovasc Prev Rehabil 2005;12:363-8.